TKT and neoplasm: Intriguingly, this technology is based on CCL5, a chemokine produced by MSCs upon contact with tumor cells, which allows the activation of the CCL5 promoter driving HSV-TK genes only in tumor-infiltrating MSCs, restricting expression of the prodrug-converting enzyme to the tumor microenvironment.